Skip to main content
. 2017 Nov 28;89(22):2245–2253. doi: 10.1212/WNL.0000000000004687

Figure 2. Main efficacy results (abobotulinumtoxinA [ABO] doses combined).

Figure 2

(A) Gastrocnemius–soleus complex (GSC) Modified Ashworth scale (MAS) and (B) physician global assessment (PGA) mean scores at baseline or week 4 and across treatment cycles and (C) mean change in comfortable barefoot walking speed from baseline and week 4 and week 12 of each cycle. Baseline refers to baseline of double-blind study, prior to first injection. Error bars in A and B show SD. aPercentage improvement from baseline. bA post hoc analysis compared change from baseline in 10-m walking speed at week 4 vs week 12 across cycles using a model for repeated measures; greater improvement was observed at week 12 compared with week 4 across cycles. DB = double-blind study; LS = least-squared; PBO = placebo.